Venetoclax for Enhancing Immune Function in CLL: Insights From Multiomic Evaluation With Matthew Cortese, MD, MPH
Expert Perspectives · Keira Smith · 2025-01-06
The 2024 American Society of Hematology (ASH) Annual Meeting showcased groundbreaking research on the effects of venetoclax on immune function in chronic lymphocytic leukemia (CLL), presented by Dr. Matthew Cortese, Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center. His study highlights the intricate relationship between CLL, immunosuppression, and the potential of venetoclax to repair immune deficiencies, paving the way for more effective combination therapies.
Venetoclax in CLL
CLL is not only a cancer of B cells, it also involves a broader immunosuppressive milieu that affects T cells, macrophages, and other immune components. Venetoclax, known for its ability to induce apoptosis in CLL cells, was investigated for its systemic effects on the immune system. By employing advanced bioinformatics and multimodal analyses, Dr. Cortese’s team revealed significant findings.
What the Study Found
The study demonstrated that venetoclax improves T cell activation, enhances natural killer (NK) cell function, and fosters a stem-like quality in T cells, enabling them to sustain more robust responses. These immune repairs are critical in the context of immunotherapy, where healthy immune cells are necessary for optimal outcomes.
Additionally, the research identified venetoclax’s role in influencing lipid metabolism and other pathways that indirectly boost immune resilience. These findings suggest that venetoclax’s benefits extend beyond directly killing CLL cells, making it a versatile tool in treating the disease.
Dr. Cortese emphasized, “We tend to forget that these drugs circulate systemically and impact other immune cells. Understanding these effects helps us optimize treatments.” This insight highlights the importance of considering off-target effects when designing treatment strategies.
Clinical Takeaway for Oncologists
Venetoclax’s ability to enhance immune fitness opens avenues for combining it with emerging therapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies, which rely on a healthy immune microenvironment for maximum efficacy. Clinicians should consider the broader immunologic benefits of venetoclax when designing treatment plans, particularly for patients eligible for immunotherapy. This research also underscores the need for advanced molecular testing to predict patient response and tailor therapies more effectively.
Dr. Cortese noted, “Our approach unlocks an entirely new field of research—predicting response and toxicity while finding better combination treatments.” This strategy not only optimizes current therapies but also lays the groundwork for innovative approaches in CLL management.
A Message for Patients
Patients with CLL should remain engaged with and informed about ongoing research. Dr. Cortese advises, “Stay plugged in and challenge your providers for answers. While this is early data, it highlights a promising future in managing CLL with more personalized and effective treatments.” This underscores the importance of patient involvement and awareness as the field evolves.
Conclusion
As oncology continues to integrate sophisticated analyses and treatments, this work presented at ASH represents a critical step toward improving outcomes for patients with CLL and other complex cancers. “We owe this progress to our patients, whose generosity in participating in research paves the way for breakthroughs,” Dr. Cortese concluded, emphasizing the vital role of patient contributions in advancing cancer care.
With these advances, venetoclax not only shows promise in treating CLL but also opens doors for developing future therapies that could lead to better outcomes and, ultimately, cures.
About Dr. Cortese
Matthew Cortese, MD, MPH, is an Assistant Professor of Oncology in the Department of Medicine-Lymphoma and the Department of Cancer Genetics and Genomics at Roswell Park Comprehensive Cancer Center. He specializes in the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell non-Hodgkin lymphoma. Dr. Cortese’s research focuses on developing a better understanding of the mechanisms of treatment resistance and the molecular mechanisms by which low-grade lymphomas transform into more aggressive high-grade types, with the goal of personalizing treatment for these diseases.